Pharmacist counters CDC antivirals for flu alert

The Centers for Disease Control's new guidance that hospitalized and high-risk patients with unconfirmed but suspected flu should be administered antivirals without waiting may cause additional medication shortages, according to a pharmacist and professor.
» See how this might impact drug shortages

FDA approves new obesity device

FDA approved the Maestro Rechargeable System, the first weight loss treatment device that targets the nerve pathway between the brain and the stomach that controls feelings of hunger and fullness. » Read how it works

Continuing Education

MTM opportunities in caring for the patient with cardiovascular disease

This month's CE activity is the last unit of a year-long CPE series, Medication Therapy Management Considerations for Adult Patients with Cardiovascular Disease. Running from February 2014 through January 2015, the series enables pharmacists to earn up to 24 hours of CPE credit with 12 monthly knowledge-based activities from the University of Connecticut School of Pharmacy and Drug Topics.

The goal of this month's activity is to empower pharmacists to engage patients with cardiovascular disease in the practices of self-management.

To read and print the article with TEST QUESTIONS, click here. To proceed to the online exams and earn up to 2 CPE credits, click here to log in with the session code 15DT01-JKF33.

Announcement: Our CE activities have moved to a new learning management system to better serve you. The login to the Online CE Center is https://web2.uconn.edu/pharmacyce/login.php. All current user registration information has been uploaded for your convenience. Current users do not need to register. To review your registration page to ensure the data is up to date or to register, go to https://web2.uconn.edu/pharmacyce/program_register.php. For a full list of courses, go to http://pharmacy.uconn.edu/academics/ce/drug-topics-and-uconn-ce/

Overall survival extended in afatinib-treated patients with specific lung cancer mutations

Afatinib extends overall survival in lung cancer patients whose tumors have the most common epidermal growth factor receptor (EGFR) mutation compared with chemotherapy, according to study results published in The Lancet Oncology from 2 independent phase 3 clinical trials in EGFR mutation-positive patients with metastatic non-small cell lung cancer (NSCLC).
» Read more

• Clinicians under-prescribing flu antiviral drugs, maybe overprescribing antibiotics

• FDA drug approvals-January 2015

RESOURCES

Latest Clinical News